- Oops!Something went wrong.Please try again later.
More Organizations Turn to CynergisTek to Validate Technical Controls and Reduce Risk
AUSTIN, Texas, September 28, 2021--(BUSINESS WIRE)--CynergisTek (NYSE American: CTEK), a leading cybersecurity firm helping organizations in highly-regulated industries navigate emerging security and privacy issues, reports a surge in multiple contracts for technical testing and certification services under their Redspin and Backbone Consulting divisions for clients across various industries including healthcare, technology, and the financial sector.
The threat landscape continues to expand and become more complex as attackers use increasingly sophisticated methods of breaching and exploiting information systems. Recently Crowdstrike reported in its latest 2021 Threat Hunting Report that attackers have moved past malware to more stealthy techniques tailor-made to evade detection. This coupled with other high-profile events like the Scripps breach and the Memorial Health attack involving the Hive ransomware has heightened organization's concern for the integrity of their enterprises. Increased testing, threat hunting, and certifying systems have taken on new emphasis. "Simply put, it’s just getting tougher and validating controls or the integrity of information assets is becoming an imperative," said Ben Denkers, Chief Innovation Officer, CynergisTek. "Technical testing and evaluation of products and controls adds an important layer of due diligence."
As a result, CynergisTek has seen an uptick in requests for technical testing and certification services, including internal and external penetration testing, web application penetration testing, and Electronic Prescriptions for Controlled Substances (EPCS) certification. Due to increased threats and regulatory requirements organizations turn to CynergisTek to perform simulated attacks against internal and external networks and web applications to find exploits where adversaries can gain entry to steal data and intellectual property. These types of services validate the effectiveness of the investment in the tools and technology implemented and can provide valuable insight for the security team to determine where to focus resources and budget. Under the Drug Enforcement Administration (DEA), practitioners, hospitals, and pharmacies who prescribe controlled substances electronically need to verify their systems and processes are conducted properly through EPCS certification to help reduce America’s substance abuse problem.
"The breadth of expertise from our Offensive Security and EPCS teams is meeting the demand from clients who are turning to CynergisTek for the assurance that these types of services provide," says Mac McMillan, CEO and President of CynergisTek. "Historically, most of our services were assessment-related and the evolution of greater demand for validation aligns with our strategy to assist clients to achieve a higher degree of resilience and offers value-added solutions to drive client expansion and revenue growth.
About CynergisTek, Inc.
CynergisTek (www.cynergistek.com), is a top-ranked cybersecurity consulting firm helping organizations in highly-regulated industries, including those in healthcare, government, and finance navigate emerging security and privacy issues. CynergisTek combines intelligence, expertise, and a distinct methodology to validate a company's security posture and ensure the team is rehearsed, prepared, and resilient against threats. Since 2004, CynergisTek has been dedicated to hiring and retaining experts who bring real-life experience and hold advanced certifications to support and educate the industry by contributing to relevant industry associations. For more information, visit www.cynergistek.com or follow us on Twitter or Linkedin.
Cautionary Note Regarding Forward Looking Statements
This release contains certain forward-looking statements relating to the business of CynergisTek, Inc.. These forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and can be identified by the use of forward-looking terminology such as "believes," "expects," "anticipates," "would," "could," "intends," "may," "will," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including but not limited to uncertainties relating to product/services development; long and uncertain sales cycles; the ability to obtain or maintain proprietary intellectual property protection; future capital requirements; competition from other providers; the ability of the Company’s vendors to continue supplying the Company with supplies and services at comparable terms and prices; the Company’s ability to successfully compete and introduce enhancements and new features that achieve market acceptance and that keep pace with technological developments; the Company’s ability to maintain its brand and reputation and retain or replace its significant customers; cybersecurity risks and risks of damage and interruptions of information technology systems; the Company’s ability to retain key members of management and successfully integrate new executives; the Company’s ability to complete acquisitions, strategic investments, entry into new lines of business, divestitures, mergers or other transactions on acceptable terms, or at all; potential risks and uncertainties relating to the existing and ultimate impact of COVID-19, including the geographic spread, the severity of the virus, the duration of the COVID-19 outbreak, actions that may be taken by governmental authorities to contain the COVID-19 outbreak or to treat its impact, and the potential negative impacts of COVID-19 on the global economy and financial markets, and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in the Company’s Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Given the risks and uncertainties, readers should not place undue reliance on any forward-looking statement and should recognize that the statements are predictions of future results which may not occur as anticipated. Many of the risks listed above have been, and may further be, exacerbated by the COVID-19 pandemic, including its impact on the healthcare industry. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described herein, as well as others not now anticipated. CynergisTek is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005443/en/
Investor Relations Contact:
Allison + Partners